PubRank

Daniel A Lawrence

Author PubWeight™ 75.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008 3.64
2 Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003 3.41
3 Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002 2.02
4 Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem 2002 1.81
5 A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood 2005 1.81
6 Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood 2006 1.72
7 Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006 1.66
8 Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008 1.62
9 Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 2002 1.44
10 A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003 1.42
11 Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002 1.34
12 A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005 1.31
13 Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J 2006 1.24
14 A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 2008 1.24
15 Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 2009 1.22
16 Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem 2008 1.21
17 Proteomic analysis of the Vibrio cholerae type II secretome reveals new proteins, including three related serine proteases. J Biol Chem 2011 1.20
18 Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003 1.14
19 New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med (Maywood) 2004 1.14
20 Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 2007 1.09
21 Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003 1.07
22 Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE 2003 1.06
23 Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem 2002 1.04
24 The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain 2012 1.04
25 Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost 2004 1.04
26 Progressive ankylosis (Ank) protein is expressed by neurons and Ank immunohistochemical reactivity is increased by limbic seizures. Lab Invest 2003 1.03
27 Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem 2004 1.02
28 Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci 2009 1.02
29 PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol 2012 1.02
30 Low density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signaling. J Biol Chem 2010 1.01
31 Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Am J Pathol 2006 1.00
32 Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med 2004 0.99
33 Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost 2004 0.97
34 Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg 2011 0.97
35 Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes. J Biol Chem 2004 0.96
36 The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Biol Chem 2007 0.95
37 A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis. J Biol Chem 2005 0.94
38 Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol 2009 0.94
39 The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes. J Biol Chem 2003 0.94
40 Plasminogen activator inhibitor-1 mitigates brain injury in a rat model of infection-sensitized neonatal hypoxia-ischemia. Cereb Cortex 2012 0.93
41 Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides 2009 0.93
42 Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 2007 0.93
43 Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem 2008 0.91
44 Sequences within domain II of the urokinase receptor critical for differential ligand recognition. J Biol Chem 2003 0.90
45 The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 2011 0.90
46 Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia. Arterioscler Thromb Vasc Biol 2009 0.89
47 PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. Breast Cancer Res 2008 0.88
48 Tissue factor and obesity, a two-way street. Nat Med 2011 0.88
49 Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem 2010 0.87
50 Identification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin. Biochem J 2007 0.87
51 Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function. J Biol Chem 2003 0.87
52 Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors. J Biol Chem 2004 0.83
53 Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling. PLoS One 2012 0.83
54 Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1. Proc Natl Acad Sci U S A 2013 0.82
55 Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts. Arterioscler Thromb Vasc Biol 2011 0.82
56 Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex. J Am Heart Assoc 2012 0.81
57 Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities. Am J Pathol 2012 0.80
58 Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. Oncogene 2002 0.80
59 Neuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women study. BMC Neurol 2007 0.80
60 Increased stroke size following MCA occlusion in a mouse model of sickle cell disease. Blood 2014 0.79
61 Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1). Bioorg Med Chem Lett 2009 0.78
62 Development of inhibitors of plasminogen activator inhibitor-1. Methods Enzymol 2011 0.78
63 Serpin mutagenesis. Methods 2004 0.78
64 uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin. Invest Ophthalmol Vis Sci 2012 0.77
65 Structural similarity of the covalent complexes formed between the serpin plasminogen activator inhibitor-1 and the arginine-specific proteinases trypsin, LMW u-PA, HMW u-PA, and t-PA: use of site-specific fluorescent probes of local environment. Protein Sci 2002 0.77
66 Sometimes a cigar is just a cigar. Blood 2010 0.75
67 Thrombomodulin and the brain: past, present, and future. Neurology 2012 0.75
68 The functional dissonance of platelets. Blood 2012 0.75
69 Amalfi to Washington D. C.--twenty years of plasminogen activator research. Thromb Haemost 2005 0.75